10/20/2026  |  BigGo Finance

https://finance.biggo.com/news/d8d48df7-bde1-4cd3-bafd-ee9d41e8ceb0 

Oracle and AstraZeneca have signed a non-binding agreement to use AI and real-world data to identify patients eligible for clinical trials, accelerate the generation of medical evidence, and feed findings back into routine care. The two sides will initially focus on oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology diseases, and rare diseases, while establishing joint governance and outcome-evaluation mechanisms. AstraZeneca CEO Pascal Soriot said the move can optimize clinical trials, while Oracle CEO Mike Sicilia is bullish on AI's application in health care. The deal extends a trend of multinational drugmakers such as Novo Nordisk and Roche adopting AI, and institutional analysts believe it could help drive orders across the CRO supply chain.

The application of artificial intelligence (AI) in health care is extending from drug molecule design all the way to patient enrollment in clinical trials. Oracle announced on the 20th that it has signed a non-binding agreement with AstraZeneca under which the two companies will evaluate the use of AI and real-world data to identify patients who meet clinical trial criteria, while accelerating the production of medical evidence and seeking to feed research results directly back into routine clinical care.

The collaboration did not disclose financial terms or a contract value and is, in nature, an exploratory letter of intent. The two sides plan to combine AstraZeneca's expertise in scientific research and therapeutics with Oracle's capabilities in health data, cloud computing, AI analytics and clinical workflows, initially targeting oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology diseases, and rare diseases. The companies will also establish joint governance mechanisms and outcome-evaluation metrics to determine whether the model can be replicated across more disease categories.

AstraZeneca CEO Pascal Soriot said the collaboration can accelerate the process from drug discovery to patient care: "We can help clinicians identify patients faster, optimize clinical trials, and continuously generate evidence throughout the entire lifecycle of a medicine."

Oracle CEO Mike Sicilia noted that health care is one of the most important application areas for AI. He believes that combining the two companies' capabilities will help accelerate research, enable more patients to participate in clinical trials, and bring relevant insights into clinical treatment more quickly.

Notably, there were earlier signs of this collaboration. Former Oracle Vice President of Health Data Intelligence Christine Swisher joined AstraZeneca on August 11 as Vice President of Enterprise Data Enablement. Her career spans health technology, AI and data science; she previously worked at Philips, conducting deep learning research that covered medical applications. The personnel move was seen by observers as a prelude to deeper data cooperation between the two companies.

Multinational drugmakers have visibly accelerated the adoption of AI across various operational areas over the past year. Novo Nordisk announced in September a collaboration with Anthropic to use its AI models and Claude Science to support drug discovery and R&D; Roche announced in March the deployment of 2,176 Nvidia Blackwell GPUs as it prepares to build one of the largest AI factories in the pharmaceutical industry. From target screening and molecule design to clinical enrollment, AI is gradually permeating every stage of new drug development.

AVIC Securities analyzed that medical companies at home and abroad are continuing to build out AI products and services, spanning medical imaging, digital pathology, clinical decision support, precision medicine, health management, medical informatization, drug R&D and even brain-computer interfaces. Deep alliances between leading pharmaceutical companies and cloud providers, using multidimensional medical data to support target screening and drug design, have significantly compressed new drug R&D cycles, making AI an important productivity tool for empowering pharmaceutical R&D.

Debon Securities, observing from a supply-chain perspective, believes that AI drug discovery has seen a dense cluster of recent developments and a steady pace of progress. AI has sharply lowered the cost of designing candidate molecules, driving growth in the number of candidates; and since nearly all AI-generated molecules must undergo wet-lab validation, this has in turn expanded orders for molecular building blocks, protein reagents, preclinical CRO and safety assessment, segments characterized by low risk and high repeat purchases. It therefore remains bullish on the order growth that AI drug discovery brings to the CRO supply chain.

In terms of industry impact, clinical trial enrollment has long been one of the most time-consuming and costly stages of new drug development, with enrollment speed directly affecting R&D timelines and cash flow. If AI and real-world data can effectively shorten patient matching time, it would amount to earlier recognition of R&D results for drugmakers, and for cloud and data platform providers it would mean a new wave of demand for medical data services. However, a non-binding agreement is still some distance from actual commercialization, and the design of the outcome-evaluation mechanism will be key to watching whether such collaborations can be scaled up.

For investors, this event extends the thread of alliances between drugmakers and technology companies seen so far this year. The near-term theme centers on AI medical data, clinical workflow software and the CRO supply chain, but most of these collaborations remain in the validation stage, and substantive revenue contributions have yet to materialize.